Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 0.62 |
| ▸ | KIT | P10721 | 6/20 | 0.54 |
| ▸ | LCK | P06239 | 3/20 | 0.54 |
| ▸ | SRC | P12931 | 3/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.54 |
| ▸ | CSF1R | P07333 | 8/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | LYN | P07948 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2679247 | 1.00 | BRAF (0.62) | BRAFKITLCKSRCMAPK14 | |
| SCHEMBL2679156 | 0.94 | BRAF (0.58) | BRAFKITLCKSRCMAPK14 | |
| SCHEMBL10054827 | 0.94 | BRAF (0.58) | BRAFKITLCKSRCMAPK14 | |
| SCHEMBL2679307 | 0.90 | KIT (0.62) | BRAFKITLCKSRCMAPK14 | |
| SCHEMBL10054793 | 0.90 | BRAF (0.63) | BRAFKITCSF1R | |
| SCHEMBL2678795 | 0.90 | BRAF (0.63) | BRAFKITCSF1R | |
| SCHEMBL10054826 | 0.88 | BRAF (0.56) | BRAFKITLCKSRCMAPK14 | |
| SCHEMBL2679325 | 0.88 | BRAF (0.56) | BRAFKITLCKSRCMAPK14 | |
| SCHEMBL2679876 | 0.86 | KIT (0.56) | BRAFKITLCKSRCMAPK14 | |
| SCHEMBL10078414 | 0.86 | MAPK14 (0.75) | BRAFKITLCKSRCMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426446-B2 | Acrylamide derivative and use thereof in manufacture of medicament | BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) | 2013-04-23 | — | — | US | disclosed |
| US-8426446-B2 | Acrylamide derivative and use thereof in manufacture of medicament | BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) | 2013-04-23 | — | — | US | disclosed |
| US-20120116075-A1 | Acrylamide Derivative And Use Thereof In Manufacture Of Medicament | BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD | 2012-05-10 | — | — | US | disclosed |
| US-20120116075-A1 | Acrylamide Derivative And Use Thereof In Manufacture Of Medicament | BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116075-A1 | Acrylamide Derivative And Use Thereof In Manufacture Of Medicament | ABL1, ABL2, BCR | BRAF 21/4885KIT 399/4885LCK 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.